Evidence-Based Preventative Medicine
The pioneer who proved therapeutic plasma exchange can reverse biological age and slow disease progression. Founding member of the American Society for Apheresis (ASFA) and The Journal of Clinical Apheresis, and author of 100+ peer-reviewed publications. His research has established the protocols and trained most physicians practicing therapeutic apheresis today.
Dobri Kiprov, M.D., H.P. (ASCP)
Founder, Global Apheresis
The Research That Changed Everything
Four decades of research translating laboratory discoveries into evidence-based clinical treatments.
J Clin Apheresis / Aging
Dr. Kiprov hypothesized that intermittent heterochronic plasma exchange could delay cellular senescence, then co-authored the landmark study proving rejuvenation of three germ layer tissues by exchanging old blood plasma with saline-albumin.
Mehdipour M, Skinner C, Wong N, ... Kiprov D, Conboy MJ, Conboy IM
Aging (Albany NY). 12, 8790-8819 (2020)
Alzheimer's & Dementia
A randomized controlled clinical trial demonstrating 52-71% slowing of Alzheimer's disease progression with plasma exchange and albumin replacement -- superior to any FDA-approved drug at the time.
Boada M, Lopez O, ... Kiprov D, ... Paez A
Alzheimer's and Dementia: June 4, 2020. DOI:10.1002/alz.12137
GeroScience
The first clinical proof that therapeutic plasma exchange reduces human biological age by 1-3 years, measured by validated epigenetic clocks and biomarker panels.
Kim D, Kiprov DD, Luellen C, et al.
GeroScience 44, 2701-2720 (2022). doi:10.1007/s11357-022-00645-w
Aging Cell
A single-blinded, randomized, placebo-controlled study with the Buck Institute analyzing multi-omic biomarkers that contribute to biological age rejuvenation in response to therapeutic plasma exchange.
Fuentealba M, Kiprov D, Schneider K, ... Furman D
Aging Cell. 2025 Aug;24(8):e70103. doi:10.1111/acel.70103
Why This Matters
Most practitioners offering plasma exchange for longevity lack formal training in therapeutic apheresis. The field is increasingly filled with unproven approaches and exaggerated claims.
Without decades of clinical experience and published research to guide treatment protocols, patients are essentially participating in uncontrolled experiments—paying premium prices for procedures that may not follow evidence-based guidelines.
Dr. Kiprov has worked in the field of Therapeutic Apheresis for more than 40 years and has published extensively on the subject. He completed fellowship training in Clinical Immunology and Immunopathology at Massachusetts General Hospital and Harvard Medical School (NIH-sponsored) and became the first physician in the United States to pass the Hemapheresis Practitioner Exam (ASCP). He serves on the Board of Directors of the International Society for Apheresis and holds the position of Chief of the Division of Immunotherapy, Emeritus at California Pacific Medical Center. He served two terms on the American Society for Apheresis (ASFA) Board of Directors and created the first ASFA educational video program. He is the recipient of three major ASFA honors: the Presidential Award for pioneering work and numerous contributions to the field, the Lecturers Award, and the Francis Morrison Memorial Award.
1985
Founded Bay Area Mobile Apheresis
First mobile therapeutic apheresis program in the United States
1992
Founded Center for Apheresis and Immunology
Advanced clinical protocols and physician training
2021
Founded Global Apheresis
Evidence-based therapeutic apheresis network
Many of today's practitioners learned therapeutic apheresis in programs Dr. Kiprov created. He and his team represent true expertise in evidence-based therapeutic apheresis—combining decades of clinical practice with rigorous published research.
40+
Years of Research
100+
Publications
17,940+
Procedures Analyzed
2x
ASFA Board Terms
Pioneer of the field with 40+ years of clinical practice, research, and the most comprehensive study of adverse reactions in therapeutic apheresis ever published.
Among the first physicians to complete a formal fellowship in Clinical Immunology. Involved in early trials of cell therapies including CAR-T cell therapies and cell vaccines.
First to publish on the effect of Therapeutic Plasma Exchange on Aging, Long COVID, and the first placebo-controlled trial of TPE in Alzheimer's disease. He has also been involved in pioneering immunotherapy trials, including early CAR-T cell therapy research.
Global Apheresis
Founded by Dr. Kiprov, Global Apheresis is where his 40 years of published research becomes accessible treatment. Every protocol is grounded in peer-reviewed evidence and delivered by physicians trained in his methods.
TPE protocols proven to reduce biological age by 1-3 years, measured by validated epigenetic clocks.
Evidence-based plasma exchange with albumin replacement, proven to slow cognitive decline by 52-71%.
Immunomodulatory therapeutic plasma exchange protocols for managing long COVID symptoms.
Comprehensive therapeutic apheresis for a broad range of immunologically-mediated disorders.
In the Media & Speaking
Dr. Kiprov is a sought-after speaker on therapeutic plasma exchange, biological aging, and evidence-based preventative medicine.
The San Francisco Standard
An in-depth look at Dr. Kiprov's pioneering work in therapeutic plasma exchange and its implications for longevity and age-related disease.
KRQE News / EIN Presswire
Press release covering the landmark clinical study demonstrating that therapeutic plasma exchange can reverse biological aging markers in human subjects.
Tallahassee Democrat / Kaplan Center
The Kaplan Center announces outpatient TPE services for patients with chronic illness, cognitive decline, and age-related conditions, expanding access to this evidence-based therapy.
Available for Speaking Engagements
Dr. Kiprov is available for speaking engagements, media interviews, and podcast appearances.
Media InquiriesSelected Publications
Key publications from over 100 peer-reviewed works spanning four decades of advancing therapeutic apheresis medicine.
Fuentealba M, Kiprov D, Schneider K, Mu WC, Kumaar PA, Kasler H, Burton JB, Watson M, Halaweh H, King CD, Yuksel ZS, Roska-Pamaong C, Schilling B, Verdin E, Furman D. Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange. Aging Cell. 2025 Aug;24(8):e70103.
DOI: 10.1111/acel.70103Kim D, Kiprov DD, Luellen C, et al.. Old Plasma Dilution Reduces Human Biological Age: A Clinical Study. GeroScience 44, 2701-2720, 2022.
DOI: 10.1007/s11357-022-00645-wMehdipour M, Etienne J, Liu C, Mehdipour T, Kato C, Conboy M, Conboy I, Kiprov DD. Attenuation of Age-Elevated Blood Factors by Repositioning Plasmapheresis: A Novel Perspective and Approach. Transfus Apher Sci. 2021 Jun;60(3):103162.
DOI: 10.1016/j.transci.2021.103162Kiprov D. Therapeutic Plasma Exchange (TPE) and Blood Products - Implications for Longevity and Disease. Transfus Apher Sci. 2021 Jun;60(3):103163.
DOI: 10.1016/j.transci.2021.103163Mehdipour M, Skinner C, Wong N, Lieb M, Liu C, Etienne J, Kato C, Kiprov D, Conboy MJ, Conboy IM. Rejuvenation of Three Germ Layers Tissues by Exchanging Old Blood Plasma with Saline-Albumin. Aging (Albany NY). 12, 8790-8819, 2020.
DOI: 10.18632/aging.103418Kiprov D. Intermittent Heterochronic Plasma Exchange as a Modality for Delaying Cellular Senescence - A Hypothesis. J Clin Apheresis 28:387-389, 2013.
DOI: 10.1002/jca.21268For Physicians
Partner with Global Apheresis to offer your patients treatment protocols backed by over 100 peer-reviewed publications.
Comprehensive training directly from Dr. Kiprov, who has trained most physicians currently practicing TPE.
Clinical protocols proven in peer-reviewed research across four decades and thousands of procedures.
Complete operational guidance and marketing support to help you build a successful TPE practice.
Join a growing network of physicians delivering evidence-based therapeutic apheresis nationwide.